US20040033187A1 - Bioactive sol-gel derived silica fibers, methods for their preparation and their use - Google Patents

Bioactive sol-gel derived silica fibers, methods for their preparation and their use Download PDF

Info

Publication number
US20040033187A1
US20040033187A1 US10/411,086 US41108603A US2004033187A1 US 20040033187 A1 US20040033187 A1 US 20040033187A1 US 41108603 A US41108603 A US 41108603A US 2004033187 A1 US2004033187 A1 US 2004033187A1
Authority
US
United States
Prior art keywords
fiber
sol
fibers
months
aged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/411,086
Inventor
Timo Peltola
Mika Jokinen
Sinikka Veittola
Antti Yli-Urpo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/411,086 priority Critical patent/US20040033187A1/en
Publication of US20040033187A1 publication Critical patent/US20040033187A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/62227Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres
    • C04B35/62231Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products obtaining fibres based on oxide ceramics
    • C04B35/6224Fibres based on silica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/025Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02Inorganic materials
    • A61L31/028Other inorganic materials not covered by A61L31/022 - A61L31/026
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03BMANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/01Manufacture of glass fibres or filaments
    • C03B37/011Manufacture of glass fibres or filaments starting from a liquid phase reaction process, e.g. through a gel phase
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03BMANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/10Non-chemical treatment
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/624Sol-gel processing
    • DTEXTILES; PAPER
    • D01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01FCHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F9/00Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
    • D01F9/08Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments of inorganic material
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2235/00Aspects relating to ceramic starting mixtures or sintered ceramic products
    • C04B2235/02Composition of constituents of the starting material or of secondary phases of the final product
    • C04B2235/30Constituents and secondary phases not being of a fibrous nature
    • C04B2235/44Metal salt constituents or additives chosen for the nature of the anions, e.g. hydrides or acetylacetonate
    • C04B2235/441Alkoxides, e.g. methoxide, tert-butoxide

Definitions

  • This invention concerns bioactive sol-gel derived silica fibers, methods for their preparation, an implantable device comprising said fibers and the use of said device for tissue guiding or bone repair.
  • the sol-gel method has widely been used as an alternative method to prepare a great variety of applications including monoliths, powders, coatings and fibers.
  • a growing field of interest has been bioceramics that can be used as implants, fillers, or drug delivery devices.
  • the fibers have been used to improve mechanical properties in different materials.
  • the bulk structure of the sol-gel derived silica fibers can be varied by controlling the degree of branching of silica clusters.
  • the heat treatment of the fibers is another known method for condensing the bulk structure.
  • the mechanical properties become better after heat-treatment at high temperatures.
  • the mechanical properties are of minor importance. If better mechanical properties are needed, it has to be noted that the biodegradation reduces after heat-treatment at high temperatures.
  • the biodegradation of the sol-gel derived silica fibers (which was not heat-treated) was studied.
  • the biodegradation of the green state fibers can be varied and controlled by adjusting the stage of spinnability (by varying the spinning moment) and the viscosity of the sol. It was found that fibers spun in the early stage of spinnability degrade more slowly in the simulated body fluid (SBF) than fibers spun at a later stage.
  • SBF simulated body fluid
  • HCA bone like calcium phosphate
  • the formation of the HCA layer can be simulated in an in vitro environment by using simulated body fluid.
  • the SBF solution contains inorganic ions in concentrations corresponding to the human blood plasma.
  • the formed HCA has several characteristics similar to the apatite in the bone tissue and it is thought to be formed by an inorganic chemical reaction in vitro similar to that occurring in the bone tissue. This in vitro bioactivity test is generally accepted to give an indication of the in vivo bioactivity. 32
  • Bioactive sol-gel-derived silica fibers are not mentioned in prior art. Such bioactive silica fibers would provide alternatives for the design of novel products, for example implantable devices to be used in tissue guiding or bone repairs.
  • the aim of this invention is to provide a bioactive sol-gel derived silica fiber.
  • the aim is particularly to provide a sol-gel derived silica fiber, the solubility and bioactivity of which can be varied within a wide range and where the solubility and bioactivity can be varied to some extent independently of each other.
  • Another object is to provide a method for the preparation of a bioactive sol-gel derived silica fiber of the aforementioned kind.
  • Still one object is to achieve an implantable device based on the aforementioned fiber, optionally loaded with a biologically active agent, wherein said device preferably is in the form of a woven or non-woven mat, a knitted fabric or a braided cord, particularly suitable for use as tissue guiding or bone repair.
  • this invention concerns a bioactive sol-gel derived silica fiber spun from a sol at a starting point of the spinning process corresponding to a sol viscosity of at least 2000 cP, after which said fiber has been subjected to i) heat treatment or ii) aging.
  • this invention concerns a method for the preparation of a bioactive sol-gel derived silica fiber, said method comprising spinning the fiber from a silica sol wherein the starting point of the spinning process corresponds to a sol viscosity of at least 2000 cP, followed by i) heat treating or ii) aging of the fiber.
  • this invention concerns an implantable device comprising a fiber according to this invention.
  • this invention concerns the use of the implantable device according to this invention for tissue guiding or bone repair.
  • FIGS. 1 a to 1 f show the SiO 2 solubility as function of immersion time in SBF for different sol-gel derived SiO 2 fibers aged for 2 weeks, 3 months and 5 months, respectively.
  • FIGS. 2 a to 2 f show the in vitro bioactivity (measured as the change of Ca concentration in the SBF solution) as function of immersion time in SBF for different sol-gel derived SiO 2 fibers aged for 2 weeks, 3 months and 5 months, respectively.
  • FIGS. 3 a to 3 c show the SiO 2 solubility as function of immersion time in SBF for different sot-gel derived SiO 2 fibers heat treated at 175° C. (a) or 250° C. (b), respectively.
  • FIGS. 4 a and 4 b show the in vitro bioactivity (measured as the change of Ca concentration in the SBF solution) as function of immersion time in SBF for different sol-gel derived SiO 2 fibers heat treated at 175° C. (a) or 250° C. (b), respectively.
  • FIG. 5 shows the viscosity of the spinning sol versus time and indicates the spinnability regime for spinning the different sol-gel derived SiO 2 fibers.
  • FIG. 6 shows the bioactivity index as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO 2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • FIG. 7 shows the SiO 2 solubility measured as saturation level of silica in SBF as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO 2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • FIG. 8 shows the SiO 2 solubility in weight-% per hour (calculated from the linear portion of the curves before the silica saturation level) in SBF as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO 2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • the effect of aging and heat treatment on the bioactivity of the fibers according to this invention is stronger for fibers spun from sols of higher viscosity than for fibers spun from sols at lower viscosity.
  • the starting point for the spinning of the fibers should preferably be at a sol viscosity of at least 3000 cP.
  • the heat treatment should be carried out for a sufficient time, for example 2 hours, in a temperature range of 150 to 250° C., preferably 150 to 200° C., most preferably about 175° C.
  • the aging should preferably be carried out at a rather low temperature, preferably at room temperature, for a period of 2 weeks to about 5 months, preferably for about 3 to 5 months.
  • the effect of aging on the solubility (biodegradability) of the fibers according to this invention is stronger for fibers spun from sols of higher viscosity than for fibers spun from sols at lower viscosity.
  • the starting point of the spinning of the fibers should preferably start at a sol viscosity of at least 3000 cP.
  • the bioactivity of the fibers shall preferably be generated by heat treatment of the fibers.
  • the fibers shall preferably be aged instead of heat treated.
  • fibers of moderate bioactivity and low solubility are desired, such fibers shall preferably be created by spinning at low ( ⁇ 3000 cP) viscosity followed by heat treatment at about 175° C.
  • a moderately bioactive fiber loaded with a biologically active agent e.g. a therapeutically active agent
  • said agent is preferably added to the sol before spinning.
  • the bioactivity is preferably created by aging of the fiber, or with low temperature heat treating in order to avoid adverse effects of the heat on the biologically active agent.
  • Preferable biologically active agents are especially agents useful to facilitate the biocompatibility of the implanted device in the mammalian body and to avoid complications after the operation.
  • useful biologically active agents can be mentioned antiinflammatory, antimicrobial and tranquilizing agent, antithrombotic agents, growth factors and the like.
  • the implantable device can be made of one single kind of fibers according to this invention.
  • the device can comprise a mixture of two or more kinds of fibers according to this invention.
  • a certain fiber may be loaded with a biologically active agent while the other fibers may be unloaded.
  • all kinds of fibers may be loaded with a biologically active agent.
  • the device can further comprise other components, for example fillers or fibers known per se. By choicing appropriate kinds and amounts of different fibers and optionally other components, implantable devices of desired properties, such as strength, bioresorbability, bioactivity etc. can be achieved.
  • the device according to this invention is in the form or a woven or non-woven mat, a knitted fabric or a braided cord.
  • the objective of the experiments was to study the effect of aging or heat treatment on the solubility (biodegradability) and the calcium phosphate formation ability (bioactivity) of the different potentially bioactive sol-gel-derived green state silica fibers.
  • Various fibers with different bulk structures were prepared by changing the composition (varying the catalyst) and controlling the stage of spinnability and viscosity of the sol.
  • the influence of aging time or temperature in the heat treating step of the fibers on the bulk structure of the samples was investigated.
  • the ability to form calcium phosphate was investigated indirectly in terms of structural changes of the fibers by the solubility test.
  • the in vitro bioactivity and solubility tests were carried out in a simulated body fluid. Dry spinning was used to prepare fibers.
  • the green state fibers were prepared using the sol-gel method and dry spinning technique.
  • the silica sols were prepared from tetraethylortosilicate (TEOS), deionised water, absolute ethanol and HNO 3 or NH 3 as catalysts.
  • the sol compositions in molar ratios of the different fibers prepared are shown in Table I.
  • TEOS 500 g was mixed with ethanol and HNO 3 with water.
  • the acid/water solution was added to the TEOS/ethanol solution under vigorous stirring and then the solution was poured into an evaporating dish.
  • the evaporating dish was kept in a water bath at a constant temperature of 40° C.
  • the sol was kept there for 20-24.5 hours depending on the used sol recipe.
  • ethanol 445-480 mL was evaporated to accelerate the reaction kinetics of the sol.
  • the preparation of FIB 3 differed from the other sols with respect to the catalyst (NH 3 was used as catalyst in addition to HNO 3 ).
  • NH 3 was added into the sol after 24 hours of aging at 40° C. The sol was vigorously stirred for 2 minutes. After stirring, the evaporation of ethanol was started.
  • Dry spinning was used to prepare sol-gel fibers.
  • the spinning solution was kept in a container whose temperature was adjustable.
  • nitrogen gas was used to push the spinning solution to a gear pump nitrogen gas was used.
  • the gear pump (Zenith 958736) with a capacity of 0.0 mL/revolution metered the spinning solution to the spinning head.
  • the spinneret was made of a gold/platinum mixture.
  • the diameter of the holes was 65 ⁇ m and the l/d ratio was 1.
  • the number of the holes was 6.
  • the distance between the spinneret and the wind-up roll was adjusted to meet the demands of each fiber.
  • the fibers were dried in an oven at 50° C. for 2 hours. The drying can also be carried out at a lower temperature, or the drying step can be left out.
  • the ready-made fibers were aged in a desiccator at room temperature ( ⁇ 25° C.) for 2 weeks or 3 or 5 months.
  • the in vitro bioactivity tests were performed using a simulated body fluid (SBF) 31 that was prepared by dissolving reagent chemicals of NaCl, NaHCO 3 , KCl, K 2 HPO 4 .3H 2 O, MgCl 2 .6H 2 O, CaCl 2 .2H 2 O and Na 2 SO 4 into deionised water.
  • SBF simulated body fluid
  • the fluid was buffered at physiological pH 7.40 at 37° C. with tris(hydroxymethyl)-aminomethane and hydrocloric acid.
  • the calcium required for the HCA formation on the SiO 2 fiber surfaces were extracted from SBF. This was indicated by the reduction of the concentration of calcium in SBF.
  • Sample solutions were monitored for calcium and silicon concentrations as a function of the immersion time. The calcium concentrations were determined with an atomic absorption spectrophotometer (AAS, Perkin-Elmer 460).
  • the silicon concentrations were analysed by a molybdenum blue-method 33 with UV-Vis spectrophotometer (Hitachi Model 100-60). The silicon analysis was based on reduction with 1-amino-2-naphtholsulfonic acid. All sample solutions were tested three times each.
  • the solubility results of the fibers aged for 2 weeks, 3 and 5 months are shown in FIGS. 1 a to 1 f and summarised in Table II. Comparing the solubility results of the different fibers aged for 2 weeks, the solubility rates (before the saturation level) and saturation levels clearly differ from each other.
  • the fibers spun in the later stage of spinnability (higher viscosity; FIB 1 (B) and FIB 2 (B)) were about ten times more soluble than the fibers having same sol compositions (Table I) but spun in the early stage of spinnability (FIB 1 (A) FIB 2 (A)). The most soluble fiber (FIB 1 (C)) was spun in the later stage of spinnability.
  • FIB 1 (C) had the same sol composition as FIB 1 (B), but the viscosity of the sol (FIB 1(C)) was increased to 15000 cP before spinning.
  • the solubility (saturation level) of the FIB 3 seemed to be a little bit lower than for the other fibers spun in the later stage of spinnability.
  • the solubility rates of FIB 1 (B), FIB 2 (B) and FIB 1 (C) are initially quite slow but start to increase faster before the saturation level is reached.
  • the stuctural stability of the fibers was investigated as a function of the aging time.
  • the solubility values were practically the same after 2 weeks, 3 and 5 months aging indicating a quite stable structure.
  • the solubility rates of FIB 2 (A) aged for 3 or 5 months were higher than the solubility rate of FIB 2 (A) aged for 2 weeks. It suggests that the fibers become more fragile as a function of the aging time.
  • the solubility rate of FIB 3 aged for 5 months was lower than the solubility rates of FIB 3 aged for 2 weeks or 3 months. This suggests a some degree of densification as a function of the aging time. As it is seen in the FIG.
  • the in vitro bioactivity is illustrated as a decrease of the calcium concentration in the SBF as a function of the time.
  • the bioactivity results are summarised in Table II. There was no direct connection between the in vitro bioactivity and SiO 2 solubility results (the silica concentration levels and saturation level). According to the silica solubility results the structure of the fibers seemed to change as a function of the aging time and so did the in vitro bioactivity.
  • FIG. 2 the immersion time ranges where the silica saturation is reached are shown (indicated by asterisks). It is clearly seen that the calcium phosphate formation starts after the silica saturation point has been reached. According to the solubility results, the silica saturation level is achieved before 7 days of immersion in the SBF for every sample. However, some fibers did not form any calcium phosphate within the 2 weeks of immersion.
  • FIGS. 6 to 8 summarize the effect of the different parameters on the bioactivity and solubility of the fibers prepared.
  • the “bioactivity index” presented in FIG. 6 refers to the in vitro bioactivity studies and can be defined as a function of a) the starting point of the descent of the Ca concentration curve and b) the difference between the initial Ca concentration and the Ca concentration after 14 days.
  • the calculation of the bioactivity index is best illustrated by referring to the following example: From FIG. 2 c it can be seen that the start of the descent of the Ca concentration curve for FIB 3 , 3 months, takes place after 5 to 7 days (6 days, as an average) time of immersion. The end point (14 days) minus the starting point (6 days) is 8. The difference between the starting Ca concentration (5.0 mg/50 ml) and the end point Ca concentration (4.15 mg/50 ml) is 0.85.
  • the structure of the fiber matrix is the most important factor controlling the in vitro bioactivity of the silica fibers.
  • the structure of the fibers can be varied using three different factors: (1) use of the spinnable sols having varying structure and size of silica polymers establishing varying viscosity levels, (2) aging of the green state fibers and (3) heat-treatment of fibers.
  • FIB1(A), FIB2(A) and FIB3 belong to the same group according to the viscosity level, but FIB1(A) and FIB2(A) are marked as 1 ⁇ , because they have been spun at 0° C., which causes increase in the viscosity.
  • FIG. 6 A general trend of the varying bioactivity is shown in FIG. 6. The higher the starting viscosity is in the spinning sol, the better is the bioactivity.
  • the solubility data of the fibers (shown in FIGS. 7 and 8) follow the same pattern. The solubility rate of silica as well as the saturation point concentration are greater as the bioactivity increases.
  • the fibers spun at ⁇ >3000 cP have good properties with respect to the bioactivity and a more porous structure which is observed in the solubility data.
  • the fibers spun at ⁇ 3000 cP have a condensed structure and they are structurally more stable (less soluble in the simulated body fluid (SBF)) and the bioactivity is clearly lower.
  • Heat-treatment at 175° C. was favourable for every sample.
  • the size and form of the silica polymers is an important factor influencing the fiber structure and these properties also are interconnected with the viscosity of the sol. At lower viscosities, the silica polymers are smaller and they are packed easier (producing more condensed structures) than larger polymer at higher viscosities.
  • the viscosity level as such has an influence on the structure. Higher viscosity may retard the orientation of the silica polymers in spinning leaving the resulting structure more porous. These factors determine the connection between the viscosity (and the size and form of the silica polymers): the higher the viscosity (the larger the polymer size), the higher solubility (more porous structure).
  • the structure is porous, it also has the longest polymers and the fiber structure is most favourable.
  • the silica polymers are best to resist the structural changes (e.g. caused by mild heat-treatment at 175° C.) although they form a more porous structure.
  • the fibers belonging to the group 2 ⁇ have almost identical properties as a function of aging and heat-treatment. These fibers provide a good example on the influence of the spinning moment on the fiber structure. They are from the recipe as the FIB1(A) and FIB2(A), but they have been spun later at higher viscosity.
  • FIB3 has intermediate properties, which are, on the other hand, quite similar to those of FIB1(B) and FIB2(B).
  • FIB3 has also a viscosity value near the regime 2 ⁇ , although lower. However, it is the only fiber sol containing NH 3 , which catalyses the condensation reactions and the viscosity increases faster than for the other samples.
  • FIB 1 (A) 0.02 1.5 0.03 1.2 c 0.03 2.0 c 12-14 10-14 7-14 2.0 d FIB 2 (A) 0.03 2.0 0.2 5.0 0.1 4.6 — f 10-14 — f 2.0 d FIB 3 1.7 44 1.4 48 0.8 32 — f 5-7 — f 2.0 e FIB 1 (B) 0.4 g 60 0.7 52 1.3 48 7-12 7-10 10-14 3.9 e FIB 2 (B) 0.4 g 58 0.8 50 1.4 44 7-12 7-10 10-14 3.0 e FIB 1 (C) 2.8 65 5.8 57 8.5 60 — f 10-14 1-5 15 d

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Structural Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Textile Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Inorganic Fibers (AREA)
  • Silicon Compounds (AREA)

Abstract

This invention relates to bioactive sol-gel derived silica fibers, methods for their preparation, an implantable device comprising said fibers and the use of said device for tissue guiding or bone repair.

Description

  • This invention concerns bioactive sol-gel derived silica fibers, methods for their preparation, an implantable device comprising said fibers and the use of said device for tissue guiding or bone repair. [0001]
  • BACKGROUND OF THE INVENTION
  • The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference. [0002]
  • The sol-gel method has widely been used as an alternative method to prepare a great variety of applications including monoliths, powders, coatings and fibers. A growing field of interest has been bioceramics that can be used as implants, fillers, or drug delivery devices. [0003]
  • The rheological properties of the silica sols and the processing of the sol-gel derived silica fibers are well known.[0004] 1-9 The most common property of the sols in the fiber spinning is a low water-to-TEOS molar ratio (about 2) (TEOS=tetraethylortho silicate or tetraethoxysilane). The low water-to-TEOS ratio indicates a formation of linear silica polymers, which is an important factor for the spinnable sols. Various sol-gel derived fibers (containing Ti, Si, Zr, Pb, Y, Mg or Al) have also been successfully prepared.5,6,10-13 The most common use for these fibers are the applications for optical and electronic purposes.14-27
  • In general, the fibers have been used to improve mechanical properties in different materials. The bulk structure of the sol-gel derived silica fibers can be varied by controlling the degree of branching of silica clusters. The heat treatment of the fibers is another known method for condensing the bulk structure. The mechanical properties become better after heat-treatment at high temperatures. In applications where the fibers are used as drug delivery device in soft tissue, the mechanical properties are of minor importance. If better mechanical properties are needed, it has to be noted that the biodegradation reduces after heat-treatment at high temperatures. In the inventors' previous article[0005] 28 the biodegradation of the sol-gel derived silica fibers (which was not heat-treated) was studied. It was found that the biodegradation of the green state fibers can be varied and controlled by adjusting the stage of spinnability (by varying the spinning moment) and the viscosity of the sol. It was found that fibers spun in the early stage of spinnability degrade more slowly in the simulated body fluid (SBF) than fibers spun at a later stage.
  • Another important property of the biomaterials, bioactivity, has been widely studied also for sol-gel-derived materials. The ability of the materials to form HCA (HCA=bone like calcium phosphate) may lead to osteoconduction and further to bone bonding in in vivo conditions.[0006] 29,30
  • The formation of the HCA layer can be simulated in an in vitro environment by using simulated body fluid. The SBF solution contains inorganic ions in concentrations corresponding to the human blood plasma.[0007] 31 The formed HCA has several characteristics similar to the apatite in the bone tissue and it is thought to be formed by an inorganic chemical reaction in vitro similar to that occurring in the bone tissue. This in vitro bioactivity test is generally accepted to give an indication of the in vivo bioactivity.32
  • Bioactive sol-gel-derived silica fibers are not mentioned in prior art. Such bioactive silica fibers would provide alternatives for the design of novel products, for example implantable devices to be used in tissue guiding or bone repairs. [0008]
  • OBJECTS AND SUMMARY OF THE INVENTION
  • The aim of this invention is to provide a bioactive sol-gel derived silica fiber. The aim is particularly to provide a sol-gel derived silica fiber, the solubility and bioactivity of which can be varied within a wide range and where the solubility and bioactivity can be varied to some extent independently of each other. [0009]
  • Another object is to provide a method for the preparation of a bioactive sol-gel derived silica fiber of the aforementioned kind. [0010]
  • Still one object is to achieve an implantable device based on the aforementioned fiber, optionally loaded with a biologically active agent, wherein said device preferably is in the form of a woven or non-woven mat, a knitted fabric or a braided cord, particularly suitable for use as tissue guiding or bone repair. [0011]
  • Thus, according to one aspect, this invention concerns a bioactive sol-gel derived silica fiber spun from a sol at a starting point of the spinning process corresponding to a sol viscosity of at least 2000 cP, after which said fiber has been subjected to i) heat treatment or ii) aging. [0012]
  • According to another aspect, this invention concerns a method for the preparation of a bioactive sol-gel derived silica fiber, said method comprising spinning the fiber from a silica sol wherein the starting point of the spinning process corresponds to a sol viscosity of at least 2000 cP, followed by i) heat treating or ii) aging of the fiber. [0013]
  • According to a further aspect, this invention concerns an implantable device comprising a fiber according to this invention. [0014]
  • Furthermore, this invention concerns the use of the implantable device according to this invention for tissue guiding or bone repair.[0015]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1[0016] a to 1 f show the SiO2 solubility as function of immersion time in SBF for different sol-gel derived SiO2 fibers aged for 2 weeks, 3 months and 5 months, respectively.
  • FIGS. 2[0017] a to 2 f show the in vitro bioactivity (measured as the change of Ca concentration in the SBF solution) as function of immersion time in SBF for different sol-gel derived SiO2 fibers aged for 2 weeks, 3 months and 5 months, respectively.
  • FIGS. 3[0018] a to 3 c show the SiO2 solubility as function of immersion time in SBF for different sot-gel derived SiO2 fibers heat treated at 175° C. (a) or 250° C. (b), respectively.
  • FIGS. 4[0019] a and 4 b show the in vitro bioactivity (measured as the change of Ca concentration in the SBF solution) as function of immersion time in SBF for different sol-gel derived SiO2 fibers heat treated at 175° C. (a) or 250° C. (b), respectively.
  • FIG. 5 shows the viscosity of the spinning sol versus time and indicates the spinnability regime for spinning the different sol-gel derived SiO[0020] 2 fibers.
  • FIG. 6 shows the bioactivity index as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO[0021] 2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • FIG. 7 shows the SiO[0022] 2 solubility measured as saturation level of silica in SBF as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • FIG. 8 shows the SiO[0023] 2 solubility in weight-% per hour (calculated from the linear portion of the curves before the silica saturation level) in SBF as function of sol viscosity at the start of fiber spinning, for sol-gel derived SiO2 fibers aged for 2 weeks, 3 months or 5 months, or heat treated at 175° C. or 250° C.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The effect of aging and heat treatment on the bioactivity of the fibers according to this invention is stronger for fibers spun from sols of higher viscosity than for fibers spun from sols at lower viscosity. Thus, in order to get a good bioactivity, the starting point for the spinning of the fibers should preferably be at a sol viscosity of at least 3000 cP. [0024]
  • The heat treatment should be carried out for a sufficient time, for example 2 hours, in a temperature range of 150 to 250° C., preferably 150 to 200° C., most preferably about 175° C. [0025]
  • If the bioactivity is created by aging of the fiber, the aging should preferably be carried out at a rather low temperature, preferably at room temperature, for a period of 2 weeks to about 5 months, preferably for about 3 to 5 months. [0026]
  • The effect of aging on the solubility (biodegradability) of the fibers according to this invention is stronger for fibers spun from sols of higher viscosity than for fibers spun from sols at lower viscosity. Thus, in order to get fibers having increased solubility, the starting point of the spinning of the fibers should preferably start at a sol viscosity of at least 3000 cP. If fibers with high bioactivity and rather low solubility are desired, the bioactivity of the fibers shall preferably be generated by heat treatment of the fibers. On the other hand, if slightly bioactive fibers with high solubility are desired, the fibers shall preferably be aged instead of heat treated. [0027]
  • If fibers of moderate bioactivity and low solubility are desired, such fibers shall preferably be created by spinning at low (<3000 cP) viscosity followed by heat treatment at about 175° C. [0028]
  • If a moderately bioactive fiber loaded with a biologically active agent, e.g. a therapeutically active agent is desired, said agent is preferably added to the sol before spinning. In this case the bioactivity is preferably created by aging of the fiber, or with low temperature heat treating in order to avoid adverse effects of the heat on the biologically active agent. [0029]
  • Preferable biologically active agents are especially agents useful to facilitate the biocompatibility of the implanted device in the mammalian body and to avoid complications after the operation. Thus, as examples of useful biologically active agents can be mentioned antiinflammatory, antimicrobial and tranquilizing agent, antithrombotic agents, growth factors and the like. [0030]
  • The implantable device can be made of one single kind of fibers according to this invention. Alternatively, the device can comprise a mixture of two or more kinds of fibers according to this invention. In this case a certain fiber may be loaded with a biologically active agent while the other fibers may be unloaded. Alternatively, all kinds of fibers may be loaded with a biologically active agent. The device can further comprise other components, for example fillers or fibers known per se. By choicing appropriate kinds and amounts of different fibers and optionally other components, implantable devices of desired properties, such as strength, bioresorbability, bioactivity etc. can be achieved. [0031]
  • According to a preferred embodiment, the device according to this invention, is in the form or a woven or non-woven mat, a knitted fabric or a braided cord. [0032]
  • The invention will be described more in detail in the Experimental section in the following non-limiting examples. [0033]
  • Experimental [0034]
  • The objective of the experiments was to study the effect of aging or heat treatment on the solubility (biodegradability) and the calcium phosphate formation ability (bioactivity) of the different potentially bioactive sol-gel-derived green state silica fibers. Various fibers with different bulk structures were prepared by changing the composition (varying the catalyst) and controlling the stage of spinnability and viscosity of the sol. The influence of aging time or temperature in the heat treating step of the fibers on the bulk structure of the samples was investigated. Furthermore, the ability to form calcium phosphate was investigated indirectly in terms of structural changes of the fibers by the solubility test. The in vitro bioactivity and solubility tests were carried out in a simulated body fluid. Dry spinning was used to prepare fibers. [0035]
  • Materials and Methods [0036]
  • Sol-Gel-Derived SiO[0037] 2 Fibers
  • The green state fibers were prepared using the sol-gel method and dry spinning technique. The silica sols were prepared from tetraethylortosilicate (TEOS), deionised water, absolute ethanol and HNO[0038] 3 or NH3 as catalysts. The sol compositions in molar ratios of the different fibers prepared are shown in Table I. TEOS (500 g) was mixed with ethanol and HNO3 with water. The acid/water solution was added to the TEOS/ethanol solution under vigorous stirring and then the solution was poured into an evaporating dish. The evaporating dish was kept in a water bath at a constant temperature of 40° C. The sol was kept there for 20-24.5 hours depending on the used sol recipe. A certain amount of ethanol (445-480 mL) was evaporated to accelerate the reaction kinetics of the sol. The preparation of FIB 3 differed from the other sols with respect to the catalyst (NH3 was used as catalyst in addition to HNO3). NH3 was added into the sol after 24 hours of aging at 40° C. The sol was vigorously stirred for 2 minutes. After stirring, the evaporation of ethanol was started.
  • After evaporation of ethanol the sols were cooled to either 20° C. or 0° C. (depending on the sample as shown in Table II). The spinning was started when a certain level of viscosity of the sol was reached. A rotational viscometer with a disc shaped spindle (Brookfield LVDV II+) was used to define the point where the spinning was started. The measurements were made at a constant shear rate of 3 rpm. To avoid breaking of the sol-gel filaments air bubbles were removed from the spinning solution under partial vacuum. [0039]
  • Dry spinning was used to prepare sol-gel fibers. The spinning solution was kept in a container whose temperature was adjustable. To push the spinning solution to a gear pump nitrogen gas was used. The gear pump (Zenith 958736) with a capacity of 0.0 mL/revolution metered the spinning solution to the spinning head. The spinneret was made of a gold/platinum mixture. The diameter of the holes was 65 μm and the l/d ratio was 1. The number of the holes was 6. The distance between the spinneret and the wind-up roll was adjusted to meet the demands of each fiber. After spinning, the fibers were dried in an oven at 50° C. for 2 hours. The drying can also be carried out at a lower temperature, or the drying step can be left out. [0040]
  • Aging [0041]
  • The ready-made fibers were aged in a desiccator at room temperature (˜25° C.) for 2 weeks or 3 or 5 months. [0042]
  • Heat Treating [0043]
  • The fibers were placed in an oven and the temperature was raised at 10° C./hour to the top temperature (175° C. or 250° C.), where it was kept for 2 hours. Thereafter the temperature was allowed to drop to room temperature. [0044]
  • SBF Tests [0045]
  • The in vitro bioactivity tests were performed using a simulated body fluid (SBF)[0046] 31 that was prepared by dissolving reagent chemicals of NaCl, NaHCO3, KCl, K2HPO4.3H2O, MgCl2.6H2O, CaCl2.2H2O and Na2SO4 into deionised water. The fluid was buffered at physiological pH 7.40 at 37° C. with tris(hydroxymethyl)-aminomethane and hydrocloric acid.
  • Three samples from each fiber batch at different aging times (shown in Table II) were used to investigate the reactions of the fibers in SBF. Each specimen (10 mg) was immersed in 50 mL of SBF in a closed polyethylene container. Three samples of SBF enclosed in bottles without a specimen was used as controls to examine the solution stability. The samples were immersed in the SBF fluid for 2 weeks, the bottles being placed in a shaking water bath (Heto SBD 50 ([0047] shake 2, 36 mm, speed=160)) having a constant temperature at 37° C.
  • Ion Concentration Analysis [0048]
  • The calcium required for the HCA formation on the SiO[0049] 2 fiber surfaces were extracted from SBF. This was indicated by the reduction of the concentration of calcium in SBF. Sample solutions were monitored for calcium and silicon concentrations as a function of the immersion time. The calcium concentrations were determined with an atomic absorption spectrophotometer (AAS, Perkin-Elmer 460). The silicon concentrations were analysed by a molybdenum blue-method33 with UV-Vis spectrophotometer (Hitachi Model 100-60). The silicon analysis was based on reduction with 1-amino-2-naphtholsulfonic acid. All sample solutions were tested three times each.
  • Results [0050]
  • Effects of Aging [0051]
  • The solubility results of the fibers aged for 2 weeks, 3 and 5 months are shown in FIGS. 1[0052] a to 1 f and summarised in Table II. Comparing the solubility results of the different fibers aged for 2 weeks, the solubility rates (before the saturation level) and saturation levels clearly differ from each other. The fibers spun in the later stage of spinnability (higher viscosity; FIB 1 (B) and FIB 2 (B)) were about ten times more soluble than the fibers having same sol compositions (Table I) but spun in the early stage of spinnability (FIB 1 (A) FIB 2 (A)). The most soluble fiber (FIB 1 (C)) was spun in the later stage of spinnability. However, in this case the medium fiber diameter is smaller than for the others (shown in Table I), which may have a slight influence on the solubility. FIB 1 (C) had the same sol composition as FIB 1 (B), but the viscosity of the sol (FIB 1(C)) was increased to 15000 cP before spinning. The solubility (saturation level) of the FIB 3 seemed to be a little bit lower than for the other fibers spun in the later stage of spinnability. As it is seen in FIGS. 1d to 1 f, the solubility rates of FIB 1 (B), FIB 2 (B) and FIB 1 (C) are initially quite slow but start to increase faster before the saturation level is reached. This suggests that the outer structure of the fibers is denser than the inner structure. This property is also seen in other fibers, but not so clearly, suggesting more similar structure between the inner and outer structure. The differences between the solubility of the inner and outer structure have a clear influence on the given solubility rates (Table II) calculated from the linear portion of the curves before the saturation level. Therefore, the saturation level is also important for reliable comparison of the solubility rates of different fibers.
  • The stuctural stability of the fibers was investigated as a function of the aging time. For the FIB 1 (A) the solubility values were practically the same after 2 weeks, 3 and 5 months aging indicating a quite stable structure. The solubility rates of FIB 2 (A) aged for 3 or 5 months were higher than the solubility rate of FIB 2 (A) aged for 2 weeks. It suggests that the fibers become more fragile as a function of the aging time. However, the solubility rate of [0053] FIB 3 aged for 5 months was lower than the solubility rates of FIB 3 aged for 2 weeks or 3 months. This suggests a some degree of densification as a function of the aging time. As it is seen in the FIG. 1 (1 d to 1 f), the solubility rates of the outer structure of FIB 1 (B), FIB 2 (B) and FIB 1 (C) increase as a function of the aging time. However, the silica saturation levels seem to decrease as a function of the aging time. The solubilities of the fibers spun in the early stage of spinnability (FIB 1(A) and FIB 2 (A)) differs from each other. However, the solubility rates and curves were nearly identical for the fibers having the same sol compositions but spun in the later stage of spinnability (FIB 1 (B) and FIB 2 (B)).
  • In FIGS. 2[0054] a to 2 f, the in vitro bioactivity is illustrated as a decrease of the calcium concentration in the SBF as a function of the time. The bioactivity results are summarised in Table II. There was no direct connection between the in vitro bioactivity and SiO2 solubility results (the silica concentration levels and saturation level). According to the silica solubility results the structure of the fibers seemed to change as a function of the aging time and so did the in vitro bioactivity.
  • In FIG. 2 the immersion time ranges where the silica saturation is reached are shown (indicated by asterisks). It is clearly seen that the calcium phosphate formation starts after the silica saturation point has been reached. According to the solubility results, the silica saturation level is achieved before 7 days of immersion in the SBF for every sample. However, some fibers did not form any calcium phosphate within the 2 weeks of immersion. [0055]
  • Effects of Heat Treatment [0056]
  • The results are shown in Table III and in the FIGS. 3[0057] a to 3 b (solubility) and FIGS. 4a to 4 b (in vitro bioactivity) for the two temperatures tested, 175 and 250° C., respectively.
  • When treated in 175° C., the solubility of all the fibers except for FIB 1 (C) decreased essentially, obviously because the structure became more dense. The speed of the HCA formation increased. When treated in 250° C., the solubility as well as the bioactivity decreased compared to that of the fibers treated in 175° C. [0058]
  • Conclusions [0059]
  • FIGS. [0060] 6 to 8 summarize the effect of the different parameters on the bioactivity and solubility of the fibers prepared. The “bioactivity index” presented in FIG. 6 refers to the in vitro bioactivity studies and can be defined as a function of a) the starting point of the descent of the Ca concentration curve and b) the difference between the initial Ca concentration and the Ca concentration after 14 days. The calculation of the bioactivity index is best illustrated by referring to the following example: From FIG. 2c it can be seen that the start of the descent of the Ca concentration curve for FIB 3 , 3 months, takes place after 5 to 7 days (6 days, as an average) time of immersion. The end point (14 days) minus the starting point (6 days) is 8. The difference between the starting Ca concentration (5.0 mg/50 ml) and the end point Ca concentration (4.15 mg/50 ml) is 0.85. The bioactivity index is the product 8×0.85=6.8.
  • Factors Determining Bioactivity [0061]
  • The structure of the fiber matrix is the most important factor controlling the in vitro bioactivity of the silica fibers. The structure of the fibers can be varied using three different factors: (1) use of the spinnable sols having varying structure and size of silica polymers establishing varying viscosity levels, (2) aging of the green state fibers and (3) heat-treatment of fibers. [0062]
  • The spinnable sol can roughly be divided into three different regimes: η<3000 cP (1α & 1β), η=3000-5000 cP (2α) and η=15 000 cP (3α). They are illustrated in FIG. 5. FIB1(A), FIB2(A) and FIB3 belong to the same group according to the viscosity level, but FIB1(A) and FIB2(A) are marked as 1α, because they have been spun at 0° C., which causes increase in the viscosity. [0063]
  • A general trend of the varying bioactivity is shown in FIG. 6. The higher the starting viscosity is in the spinning sol, the better is the bioactivity. In addition, the solubility data of the fibers (shown in FIGS. 7 and 8) follow the same pattern. The solubility rate of silica as well as the saturation point concentration are greater as the bioactivity increases. [0064]
  • Another clearly observable property is the influence of the heat-treatment. As compared to the green state fibers (dried at 50° C. & aged at RT), increased bioactivity is achieved for every sample as they are heat-treated at 175° C. and it declines after the heat-treatment at 250° C. [0065]
  • The aging of the fibers had no common behaviour with respect to the in vitro bioactivity. The fibers spun at lower viscosities (1α) only show that the bioactivity is not very good and the differences are not great. For the fibers spun at higher viscosities (1β & 2α), the bioactivity shows best results after 3 months of aging. In addition, the properties of these fibers seem to vary according to same pattern as they are aged and heat-treated. The fiber (FIB1(C)) spun at the highest viscosity (3α) becomes better with aging (up to 5 months). [0066]
  • As a summary, it can be said that the fibers spun at η>3000 cP have good properties with respect to the bioactivity and a more porous structure which is observed in the solubility data. The fibers spun at η<3000 cP have a condensed structure and they are structurally more stable (less soluble in the simulated body fluid (SBF)) and the bioactivity is clearly lower. Heat-treatment at 175° C. was favourable for every sample. [0067]
  • Factors Determining the Structure of the Fibers [0068]
  • Within the same recipe and also the viscosity groups, there are differences depending on the small structural changes. All the factors which have already been mentioned have an influence on the fiber structure (size and form of the silica polymers in the sol, the viscosity of the sol, aging time and heat-treatment). [0069]
  • The size and form of the silica polymers is an important factor influencing the fiber structure and these properties also are interconnected with the viscosity of the sol. At lower viscosities, the silica polymers are smaller and they are packed easier (producing more condensed structures) than larger polymer at higher viscosities. [0070]
  • Also the viscosity level as such has an influence on the structure. Higher viscosity may retard the orientation of the silica polymers in spinning leaving the resulting structure more porous. These factors determine the connection between the viscosity (and the size and form of the silica polymers): the higher the viscosity (the larger the polymer size), the higher solubility (more porous structure). [0071]
  • The influence of the heat-treatment at 175 or 250° C. is obvious. A morphologically suitable surface for HCA formation is produced at 175° C. The heat treatment consolidates the fiber matrix and makes the structure less soluble in SBF. However, FIB1(C) which was spun at high viscosity seem to obtain the same favourable properties with 5 months' aging. This fiber has the highest solubility of all and hence also the most porous structure. However, the silica saturation levels are so high that it is difficult to use them reliably in comparisons. On the other hand, the solubility rates provide information from the fiber surface and the analogy for the aging and heat-treatment is same as for the other samples. Although the structure is porous, it also has the longest polymers and the fiber structure is most favourable. In other words, the silica polymers are best to resist the structural changes (e.g. caused by mild heat-treatment at 175° C.) although they form a more porous structure. [0072]
  • The changes observed within the same viscosity groups or in aging for a particular recipe have various explanations. The structures of the sols and fibers belonging to the first group, 1 α (FIB1(A) and FIB2(A)) are slightly different. The solubility data (FIGS. 7 and 8) shows (indirectly) that FIB2(A) is more porous than FIB1(A). Also transmission electron micrographs verify this fact. The sol composition is already slightly different, FIB2(A) contains more catalysts (nitric acid) than FIB1(A). The reactions proceed a bit faster for FIB2(A), which produces more branched polymers and hence more porous structure. Also during aging there are differences due to catalyst concentration and still proceeding reactions. [0073]
  • The fibers belonging to the group 2α (FIB1(B) ja FIB2(B)) have almost identical properties as a function of aging and heat-treatment. These fibers provide a good example on the influence of the spinning moment on the fiber structure. They are from the recipe as the FIB1(A) and FIB2(A), but they have been spun later at higher viscosity. [0074]
  • FIB3 has intermediate properties, which are, on the other hand, quite similar to those of FIB1(B) and FIB2(B). FIB3 has also a viscosity value near the regime 2α, although lower. However, it is the only fiber sol containing NH[0075] 3, which catalyses the condensation reactions and the viscosity increases faster than for the other samples.
  • It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive. [0076]
    TABLE I
    Sol Compositions in Molar Ratios and Cross-Sectional
    Diameters of the Fibers
    Diameters of the
    fibersa
    Symbol of Medium
    the Fiber r = H2O/ EtOH/ HNO3/ NH3/ min.-max. Value
    Samples TEOS TEOS TEOS TEOS (μm) (μm)
    FIB 1 (A) 2 1 0.036 0 39-79 59
    FIB 2 (A) 2 1 0.1 0 30-82 53
    FIB 3 2 1 0.1 0.01 21-68 39
    FIB 1 (B) 2 1 0.036 0 34-60 48
    FIB 2 (B) 2 1 0.1 0 26-67 52
    FIB 1 (C) 2 1 0.036 0 14-50 23
  • [0077]
    TABLE II
    In vitro solubility and bioactivity for aged fibers
    Calcium Phosphate Formation
    Symbol of SiO2 (fiber matrix) solubility Begins
    the Fiber 2 weeks 3 months 5 months 2 weeks/ 3 months/ 5 months/ Viscosity/
    Samples wt-%/ha sl.b/wt-% wt-%/ha sl.b/wt-% wt-%/ha sl.b/wt-% d d d Pas
    FIB 1 (A) 0.02 1.5 0.03 1.2c 0.03 2.0c 12-14 10-14  7-14 2.0d
    FIB 2 (A) 0.03 2.0 0.2 5.0 0.1 4.6 f 10-14 f 2.0d
    FIB 3 1.7 44 1.4 48 0.8 32 f 5-7 f 2.0e
    FIB 1 (B) 0.4g 60 0.7 52 1.3 48  7-12  7-10 10-14 3.9e
    FIB 2 (B) 0.4g 58 0.8 50 1.4 44  7-12  7-10 10-14 3.0e
    FIB 1 (C) 2.8 65 5.8 57 8.5 60 f 10-14 1-5 15d
  • [0078]
    TABLE III
    In vitro solublilty and bioactivity for heat treated
    Calcium Phosphate
    Symbol of SiO2 (fiber matrix) solubility Formation Begins
    the Fibre 175° C. 250° C. 175° C./ 250° C./
    Samples (wt-%/h)a sl.b/(wt-%) (wt-%/h)a sl.b/(wt-%) d d
    FIB 1 (A) 0.0 0.0 0.0 0.0  7-12 7-14
    FIB 2 (A) 0.0 0.0 0.0 0.0  7-12 d
    FIB 3 0.03 4.0 0.0004 c 1-5 7-12
    FIB 1 (B) 0.4 11 0.0005 c 1-5 5-7 
    FIB 2 (B) 0.6 14 0.0004 c 1-5 7-12
    FIB 1 (C) 7.8 65 0.4 15 1-5 5-7 
  • References [0079]
  • 1. Hashimoto T. Kamiya K, Nasu H. Strengthening of sol-gel-derived SiO[0080] 2 glass fibers by incorporating colloidal silica particles. J. Non-Cryst Sol 1992;143:31-39.
  • 2. Pozo de Fernandez M E, Kang C, Mangonon P L. Process ceramic fibers by sol-gel. Chem Eng Prog 1993;9:49-53. [0081]
  • 3. Sakka S, Kamiya K. The sol-gel transition in the hydrolysis of metal alkoxides in relation to the formation of glass fibers and films. J Non-Cryst Sol 1982;48:31-46. [0082]
  • 4. Sakka S, Kozuka H. Rheology of sols and fiber drawing. J Non-Cryst Sol 1988;100:142-153. [0083]
  • 5. Shin D -Y, Han S -M. Spinnability and rheological properties of sols derived from Si(OC[0084] 2H5)4 and Zr(O-nC3H7)4 solutions. J Sol-Gel Sci Tech 1994;1:267-273.
  • 6. Sowman H G. A new era in ceramic fibers via sol-gel technology. Cer Bull 1988;67:1911-1916. [0085]
  • 7. Sacks M D, Sheu R -S. Rheological properties of silica sol-gel materials. J Non-Cryst Sol 1987;92:383-396. [0086]
  • 8. Hasegawa I, Nakamura T, Motojima S, Kajiwara M. Synthesis of silicon carbide fibers by sol-gel processing. J Non-Cryst Sol 1997;8:577-579. [0087]
  • 9. Brinker C J, Scherer G W. Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing. Academic Press Inc. San Diego. Calif. USA; 1990. p 204-209. [0088]
  • 10. Kamiya K, Tanimoto K, Toshinobu Y. Preparation of TiO2 fibers by hydrolysis and polycondensation of Ti(O-i-C[0089] 3H7)4. J Mat Sci Lett 1986;5:402-404.
  • 11. Glaubitt W, Watza W, Scholz H, Sporn D. Sol-gel processing of functional and structural ceramic oxide fibers. J Sol-Gel Sci Tech 1997;8:29-33. [0090]
  • 12. Muralidharan B G, Agrawal D C. Sol-gel derived TiO[0091] 2-SiO2 fibers. J Sol-Gel Sci Tech 1997;9:85-93.
  • 13. Toyoda M, Hamaji Y, Tomono K. Fabrication of PbTiO[0092] 3 ceramic fibers by sol-gel processing. J Sol-Gel Sci Tech 1997;9:71-84.
  • 14. Sakka S. Sol-gel processing of insulating, electroconducting and superconducting fibers. 3 Non-Cryst Sol 1990;121:417-423. [0093]
  • 15. Del Olmo L, Caldaza M L. PbTiO[0094] 3 ceramic fibers prepared from a sol-gel process as piezoelectric materials. J Non-Cryst Sol 1990;121:424-427.
  • 16. Yoko T, Kamiya K, Kanaka K. Preparation of multiple oxide BaTiO[0095] 3 fibers by the sol-gel method. J Mat Sci 1990;25:3922-3929.
  • 17. Katayama S, Sekine M. Fabrication of superconducting YBa[0096] 2Cu3O7-x fibers by the sol-gel method using metal alkoxides. J Mater Res 1991;6:1629-1633.
  • 18. Venkatasusubramanian N, Wade B, Desai P, Abhiraman. Synthesis and characterization of spinnable sol-gel derived polyborates. J Non-Cryst Sol 1991;130:144-156. [0097]
  • 19. Selvaraj U, Prasadarao A V, Komarneni S, Brooks K, Kurtz S. Sol-Gel processing of PbTiO[0098] 3 and Pb(Zr0.52Ti0.48)O3 fibers. J Mat Res 1992;7:992-996.
  • 20. Yogo T, Iwahara H. Synthesis of α-alumina fiber from modified aluminium alkoxide precursor. J Mat Sci 1992;27:1499-1504. [0099]
  • 21. Seddon A B. Applicability of sol-gel processing in production of silica based optical fibers. Mat Sci Tech 1993;9:729-736. [0100]
  • 22. Emig G, Fitzer E, Zimmerman-Chopin R. Sol-gel process for spinning of continuous (Zr,Ce)O[0101] 2 fibers. Mat Sci Eng 1994;A189:311-317.
  • 23. Emig G, Wirth R, Zimmerman-Chopin R. Sol/gel-based precursors for manufacturing refractory oxide fibers. J Mat Sci Lett 1994;29:4559-4566. [0102]
  • 24. Chiou Y H, Tsai M T, Shih H C. The preparatin of alumina fiber by sol-gel processing. J Mat Sci 1994;29:2378-2388. [0103]
  • 25. Narang U, Gvishi R, Bright F V, Prasad P N. Sol-gel-derived micron scale optical fibers for chemical sensing. J Sol-Gel Sci Tech 1996;6:113-119. [0104]
  • 26. Hasegawa I, Nakamura T. Kajiwara M, Motojima S. Synthesis of silicon carbide fibers by sol-gel processing. J Sol-Gel Sci Tech 1997;8:577-579. [0105]
  • 27. Matejec V, Hayer M, Pospísilová M, Kasík I. Preparation of optical cores of silica optical fibers by the sol-gel method. J Sol-Gel Sci Tech 1997;8:889-893. [0106]
  • 28. Jokinen M, Peltola T, Veittola S, Rahiala H, Rosenholm J B. Biodegradable ceramic fibres from silica sols. J Eur Ceram Soc (submitted). [0107]
  • 29. Hench L. Bioactive ceramics: Theory and clinical applications. Bioceramics 1994;7:3-14. [0108]
  • 30. Voigt C, Müller-Mai C, Kandilakis K, Kangasniemi I, Yli-Urpo A, Gross U. Biological reaction after implantation of sol-gel.activated titanium cylinders in the distal epiphysis of the rabbit femur. [0109] 13 TH European Conference on Biomaterials. Göteborg. Sweden; 1997. p 45.
  • 31. Li P, Ohtsuki C, Kokubo T, Nakanishi K, Soga N, Kanamura T, Yamamuro T. Apatite formation induced by silica gel in a simulated body fluid. J Am Ceram Soc 1992;75:2094-97. [0110]
  • 32. Kokubo T, Kushitani, H. Sakka S, Kitsugi T, Yamamuro T. Solutions able to reproduce in vivo surface-structure changes in bioactive glass-ceramic A-W[0111] 3. J Biomed Mater Res 1990;24:721.
  • 33. Koch O G, Koch-Dedic G A. Handbuch der Spurenanalyse. Berlin: Springer-Verlag; 1974.p 1105. [0112]
  • 34. Rehman I, Bonfield W. Characterization of hydroxyapatite and carbonated apatite by photo acoustic FTIR spectroscopy. J Mater Science. Mater Medicine 1997;8:1-4. [0113]
  • 35. Peltola T, Jokinen M, Rahiala H. Levänen E, Rosenholm J B, Kangasniemi I, Yli-Urpo A. Calcium phosphate formation on porous sol-gel-derived SiO[0114] 2 and CaO—P2O5—SiO2 substrates in vitro. J Biomed Mater Res 1999;44:12-21.
  • 36. Pereira M M, Hench L L. Mechanisms of hydroxyapatite formation on porous get-silica substrates. J Sol-Gel Sci Tech 1996;7:59-68. [0115]
  • 37. Andersson Ö H, Kangasniemi I. Calcium phosphate formation at the surface of bioactive glass in vitro. J Biomed Mater Res 1991;25:1019-1030. [0116]
  • 38. Peltola T. Jokinen M, Rahiala H, Pätsi M, Heikkilä J, Kangasniemi I, Yli-Urpo A. Effect of aging time of sol on structure and in vitro calcium phosphate formation of sol-gel derived titania films. J Biomed Mater Res (submitted). [0117]
  • 39. Jokinen M, Pätsi M, Rahiala H, Peltola T, Ritala M, Rosenholm Jarl B. influence of sol and surface properties on in vitro bioactivity of sol-gel derived TiO[0118] 2 and TiO2—SiO2 films deposited by dip coating method. J Biomed Mater Res 1998;42:295-302.

Claims (29)

1. A method for the preparation of a bioactive sol-gel derived silica fiber, said method comprising spinning the fiber from a silica sol wherein the starting point of the spinning process corresponds to a sol viscosity of at least 2000 cP, followed by i) heat treating or ii) aging of the fiber.
2. The method according to claim 1 wherein the viscosity is at least 3000 cP.
3. The method according to claim 1 wherein the fiber is heat treated for a sufficient period of time in a temperature in the range 150 to 250° C.
4. The method according to claim 3 wherein the temperature range is 150 to 200° C., preferably about 175° C.
5. The method according to claim 2 wherein the fiber is heat treated for a sufficient period of time in a temperature in the range 150 to 250° C.
6. The method according to claim 5 wherein the temperature range is 150 to 200° C., preferably about 175° C.
7. The method according to claim 1 wherein the fiber is aged for about 2 weeks to 5 months.
8. The method according to claim 7 wherein the fiber is aged for about 3 to 5 months.
9. The method according to claim 2 wherein the fiber is aged for about 2 weeks to 5 months.
10. The method according to claim 9 wherein the fiber is aged for about 3 to 5 months.
11. A bioactive sol-gel derived silica fiber spun from a sol at a starting point of the spinning process corresponding to a sol viscosity of at least 2000 cP, after which said fiber has been subjected to i) heat treatment or ii) aging.
12. The fiber according to claim 11 wherein said viscosity is at least 3000 cP.
13. The fiber according to claim 11 wherein said fiber has been heat treated for a sufficient period of time in a temperature in the range 150 to 250° C.
14. The fiber according to claim 13, said fiber having been heat treated in the temperature range 150 to 200° C., preferably about 175° C.
15. The fiber according to claim 12 wherein said fiber has been heat treated for a sufficient period of time in a temperature in the range 150 to 250° C.
16. The fiber according to claim 15, said fiber having been heat treated in the temperature range 150 to 200° C., preferably about 175° C.
17. The fiber according to claim 11 wherein said fiber has been aged for about 2 weeks to 5 months.
18. The fiber according to claim 17 wherein said fiber has been aged for about 3 to 5 months.
19. The fiber according to claim 12 wherein said fiber has been aged for about 2 weeks to 5 months.
20. The fiber according to claim 19 wherein said fiber is aged for about 3 to 5 months.
21. The fiber according to any of the claims 11 to 20 wherein said fiber also comprises a biologically active agent.
22. An implantable device comprising a fiber according to any one of the claims 11 to 20.
23. An implantable device comprising a mixture of two or more kinds of fibers according to any one of the claims 11 to 20.
24. The device according to claim 22 in the form or a woven or non-woven mat, a knitted fabric or a braided cord.
25. The device according to claim 23 in the form or a woven or non-woven mat, a knitted fabric or a braided cord.
26. An implantable device comprising a fiber according to a any of the claims 11 to 20 wherein said fiber also comprises a biologically active agent.
27. An implantable device comprising a mixture of two or more kinds of fibers according to any of the claims 11 to 20, wherein one of more kinds of fibers also contain a biologically active agent.
28. A method of using a device according to claim 22 for tissue guiding or bone repair.
29. A method of using a device according to claim 26 for tissue guiding or bone repair.
US10/411,086 1999-12-01 2003-04-11 Bioactive sol-gel derived silica fibers, methods for their preparation and their use Abandoned US20040033187A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/411,086 US20040033187A1 (en) 1999-12-01 2003-04-11 Bioactive sol-gel derived silica fibers, methods for their preparation and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/452,379 US6632412B2 (en) 1999-12-01 1999-12-01 Bioactive sol-gel derived silica fibers and methods for their preparation
US10/411,086 US20040033187A1 (en) 1999-12-01 2003-04-11 Bioactive sol-gel derived silica fibers, methods for their preparation and their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/452,379 Division US6632412B2 (en) 1999-12-01 1999-12-01 Bioactive sol-gel derived silica fibers and methods for their preparation

Publications (1)

Publication Number Publication Date
US20040033187A1 true US20040033187A1 (en) 2004-02-19

Family

ID=23796232

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/452,379 Expired - Lifetime US6632412B2 (en) 1999-12-01 1999-12-01 Bioactive sol-gel derived silica fibers and methods for their preparation
US10/411,086 Abandoned US20040033187A1 (en) 1999-12-01 2003-04-11 Bioactive sol-gel derived silica fibers, methods for their preparation and their use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/452,379 Expired - Lifetime US6632412B2 (en) 1999-12-01 1999-12-01 Bioactive sol-gel derived silica fibers and methods for their preparation

Country Status (7)

Country Link
US (2) US6632412B2 (en)
EP (1) EP1268893B1 (en)
AT (1) ATE339535T1 (en)
AU (1) AU1866801A (en)
DE (1) DE60030777T2 (en)
ES (1) ES2270883T3 (en)
WO (1) WO2001040556A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7623340B1 (en) * 2006-08-07 2009-11-24 Nanotek Instruments, Inc. Nano-scaled graphene plate nanocomposites for supercapacitor electrodes
US9862940B2 (en) 2007-01-15 2018-01-09 Bayer Intellectual Property Gmbh Silica sol material for producing bilogically degradable and/or resorbable silica gel materials, the production and use thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1144323B1 (en) * 1999-02-22 2007-07-25 DelSiTech Oy Biodegradable ceramic fibres from silica sols
CA2555179A1 (en) * 2004-02-27 2005-09-09 Delsitech Oy Method for preparing adjustably bioresorbable sol-gel derived sio2
US7189409B2 (en) * 2004-03-09 2007-03-13 Inion Ltd. Bone grafting material, method and implant
JP2008520567A (en) 2004-11-16 2008-06-19 スリーエム イノベイティブ プロパティズ カンパニー Dental fillers, methods and compositions comprising caseinate
CA2587275A1 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental fillers and compositions including phosphate salts
CA2588103A1 (en) 2004-11-16 2006-05-26 3M Innovative Properties Company Dental compositions with calcium phosphorus releasing glass
AU2005306869B2 (en) 2004-11-16 2011-11-10 3M Innovative Properties Company Dental fillers including a phosphorus­containing surface treatment
US7682577B2 (en) 2005-11-07 2010-03-23 Geo2 Technologies, Inc. Catalytic exhaust device for simplified installation or replacement
US7682578B2 (en) 2005-11-07 2010-03-23 Geo2 Technologies, Inc. Device for catalytically reducing exhaust
DE102005063127B3 (en) * 2005-12-30 2007-08-23 Universität Hamburg Micro and nano tips and methods for their production
US7722828B2 (en) 2005-12-30 2010-05-25 Geo2 Technologies, Inc. Catalytic fibrous exhaust system and method for catalyzing an exhaust gas
EP2023893B1 (en) 2006-05-23 2018-03-14 DelSiTech Oy Method for storing silica-based material
EP1872806A1 (en) * 2006-06-28 2008-01-02 Vivoxid Oy Implant, its uses and methods for making it
WO2008000888A2 (en) * 2006-06-28 2008-01-03 Vivoxid Oy Implant containing a source of oxygen
FI20070174A0 (en) * 2007-02-28 2007-02-28 Delsitech Oy A process for the preparation of silica compositions, silica compositions and their uses
US8790707B2 (en) 2008-12-11 2014-07-29 3M Innovative Properties Company Surface-treated calcium phosphate particles suitable for oral care and dental compositions
US20100162771A1 (en) * 2008-12-31 2010-07-01 Zircoa, Inc Method of forming ceramic strings and fibers
DE102010008981A1 (en) * 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Silicon-containing, biodegradable material for pro-angiogenic therapy
US9333908B2 (en) 2013-11-06 2016-05-10 Frazier Cunningham, III Parking signaling system

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683128A (en) * 1985-06-27 1987-07-28 Nitto Chemical Industry Co., Ltd. Process for manufacturing high purity silica
US5629186A (en) * 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US5834007A (en) * 1993-09-16 1998-11-10 Ogita Biomaterial Laboratories Co. Ltd. Wound-covering material and wound-covering composition
US6228437B1 (en) * 1998-12-24 2001-05-08 United Technologies Corporation Method for modifying the properties of a freeform fabricated part

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19609551C1 (en) * 1996-03-12 1997-07-17 Fraunhofer Ges Forschung Fibres with controllable rate of biodegradation, resorbability and toxicity
EP1618896A3 (en) 1996-05-29 2010-07-14 DelSiTech Oy Dissolvable oxides for biological applications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683128A (en) * 1985-06-27 1987-07-28 Nitto Chemical Industry Co., Ltd. Process for manufacturing high purity silica
US5834007A (en) * 1993-09-16 1998-11-10 Ogita Biomaterial Laboratories Co. Ltd. Wound-covering material and wound-covering composition
US5629186A (en) * 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US6228437B1 (en) * 1998-12-24 2001-05-08 United Technologies Corporation Method for modifying the properties of a freeform fabricated part

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7623340B1 (en) * 2006-08-07 2009-11-24 Nanotek Instruments, Inc. Nano-scaled graphene plate nanocomposites for supercapacitor electrodes
US9862940B2 (en) 2007-01-15 2018-01-09 Bayer Intellectual Property Gmbh Silica sol material for producing bilogically degradable and/or resorbable silica gel materials, the production and use thereof

Also Published As

Publication number Publication date
EP1268893B1 (en) 2006-09-13
US6632412B2 (en) 2003-10-14
DE60030777D1 (en) 2006-10-26
ES2270883T3 (en) 2007-04-16
EP1268893A1 (en) 2003-01-02
US20020064493A1 (en) 2002-05-30
ATE339535T1 (en) 2006-10-15
DE60030777T2 (en) 2007-09-06
AU1866801A (en) 2001-06-12
WO2001040556A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
US6632412B2 (en) Bioactive sol-gel derived silica fibers and methods for their preparation
Peltola et al. Influence of sol and stage of spinnability on in vitro bioactivity and dissolution of sol–gel-derived SiO2 fibers
Kaur et al. Mechanical properties of bioactive glasses, ceramics, glass-ceramics and composites: State-of-the-art review and future challenges
Kim et al. Production and potential of bioactive glass nanofibers as a next‐generation biomaterial
AU2007202221B2 (en) Bioactive glass compositions
Kitsugi et al. Bone bonding behavior of MgO CaO SiO2 P2O5 CaF2 glass (mother glass of A· W‐glass‐ceramics)
KR100791518B1 (en) Production and potential of bioactive glass nanofibers as a next-generation biomaterial
Kawata et al. Development of porous ceramics with well-controlled porosities and pore sizes from apatite fibers and their evaluations
Ramanan et al. A study of hydroxyapatite fibers prepared via sol–gel route
Daraei Production and characterization of PCL (Polycaprolactone) coated TCP/nanoBG composite scaffolds by sponge foam method for orthopedic applications
JPS60153868A (en) Biologically decomposable artificial accessory and its production
JP2010507413A (en) Implant material
Nagrath et al. Bioactive glass fiber fabrication via a combination of sol-gel process with electro-spinning technique
CN105819697A (en) Biocompatible phosphate based continuous glass fiber and fabric prepared from same
RU2496804C2 (en) Nontoxic polysiloxane material for making articles containing biodegradable and/or bioactive polysiloxane material, production and use thereof
AU764663C (en) Biodegradable ceramic fibres from silica sols
Peltola et al. In vitro bioactivity and structural features of mildly heat‐treated sol‐gel‐derived silica fibers
CN105818492A (en) Biological reactive phosphate based continuous glass fiber textile composite and application thereof
Zhou et al. Bioactivity of bioresorbable composite based on bioactive glass and poly-L-lactide
Adam et al. Effect of varying phosphate content on the structure and properties of sol-gel derived SiO2-CaO-P2O5 bio-glass
Jokinen et al. Adjustable biodegradation for ceramic fibres derived from silica sols
Qi et al. The effect of ethenyltrimethoxysilane modification of nano bioactive glass on the physiochemical and mechanical properties and in vitro bioactivity of poly (lactide-co-glycolide)/poly (trimethylene carbonate) composite
Song et al. Preparation of hollow bioactive glass nanofibers by a facile electrospinning method
Kursawe et al. Biodegradable silica fibers from sols
Veláquez-González et al. Effect of Ta2O5 content on the microstructural properties of 45S5 bioglass glass-ceramic scaffolds

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION